Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Given SFDA Approval to Start Clinical Trial of Innovative Antibiotic

publication date: Jan 22, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharma received approval from the SFDA to begin clinical trials of the company’s new antibiotic, benapenem, a Category 1.1 drug that is a member of the carbapenem class of antibiotics. Both the APIs and injection form of the drug are patented. Sihuan said the antibiotic will begin its clinical trial in the first half of 2013, the company’s third Category 1 innovative drug to enter human trials. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors